Fumiaki Isohashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fumiaki Isohashi has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
Yasuo Yoshioka
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Japan
41 shared publicationsKazuhiko Ogawa
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Japan
32 shared publicationsOsamu Suzuki
Department of Radiation Oncology, Osaka University Graduate School of Medicine, Osaka, 565-0871, Japan
26 shared publicationsTadashi Kimura
Department of Gynecology and Obstetrics, Osaka University Graduate School of Medicine, Suita, Japan
22 shared publicationsMasahiko Koizumi
19 shared publicationsKoji Konishi
18 shared publications
Latest Publications
- 7 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10) , e70653
Younger Age Is Associated With Slower PSA Decline After Low‐Dose‐Rate Brachytherapy for Localized Prostate Cancer
Objectives: To evaluate the association of age with PSA kinetics and biochemical control after low‐dose‐rate brachytherapy (LDR‐BT). Methods: We retrospectively analyzed 347 patients treated with LDR‐BT alone without androgen deprivation therapy between 2004 and 2015. Longitudinal PSA changes were evaluated using linear mixed‐effects models with natural cubic splines for time. Age was modeled as a continuous fixed effect, including interactions with the spline terms for time. Time to PSA nadir < 0.2 ng/mL was evaluated using Cox proportional hazards models, whereas biochemical recurrence was evaluated using Fine–Gray competing‐risk regression with death treated as a competing event. Results: Younger age was significantly associated with slower PSA decline over 5 years ( p < 0.001). Each 1‐year increase in age was associated with model‐estimated PSA levels relative to baseline that were 4.6%, 6.4%, and 4.3% lower at 1, 3, and 5 years, respectively. This association remained significant after adjustment for Gleason grade group and treatment era and after excluding patients with PSA bounce (both p < 0.001). Median time to PSA nadir < 0.2 ng/mL was 54 months in patients aged < 65 years and 36 months in those aged ≥ 75 years. Increasing age was associated with earlier achievement of PSA nadir < 0.2 ng/mL (HR 1.04 per year, 95% CI 1.02–1.06) but was not significantly associated with biochemical recurrence. Conclusions: Age was significantly associated with PSA kinetics following LDR‐BT, with younger patients showing slower PSA decline and a delayed achievement of PSA nadir < 0.2 ng/mL. However, these age‐related differences were not associated with biochemical recurrence.
- 7 October 2026
- Published by Wiley in International Journal of Urology
- Vol. 33 (10) , e70653
Younger Age Is Associated With Slower PSA Decline After Low‐Dose‐Rate Brachytherapy for Localized Prostate Cancer
Objectives: To evaluate the association of age with PSA kinetics and biochemical control after low‐dose‐rate brachytherapy (LDR‐BT). Methods: We retrospectively analyzed 347 patients treated with LDR‐BT alone without androgen deprivation therapy between 2004 and 2015. Longitudinal PSA changes were evaluated using linear mixed‐effects models with natural cubic splines for time. Age was modeled as a continuous fixed effect, including interactions with the spline terms for time. Time to PSA nadir < 0.2 ng/mL was evaluated using Cox proportional hazards models, whereas biochemical recurrence was evaluated using Fine–Gray competing‐risk regression with death treated as a competing event. Results: Younger age was significantly associated with slower PSA decline over 5 years ( p < 0.001). Each 1‐year increase in age was associated with model‐estimated PSA levels relative to baseline that were 4.6%, 6.4%, and 4.3% lower at 1, 3, and 5 years, respectively. This association remained significant after adjustment for Gleason grade group and treatment era and after excluding patients with PSA bounce (both p < 0.001). Median time to PSA nadir < 0.2 ng/mL was 54 months in patients aged < 65 years and 36 months in those aged ≥ 75 years. Increasing age was associated with earlier achievement of PSA nadir < 0.2 ng/mL (HR 1.04 per year, 95% CI 1.02–1.06) but was not significantly associated with biochemical recurrence. Conclusions: Age was significantly associated with PSA kinetics following LDR‐BT, with younger patients showing slower PSA decline and a delayed achievement of PSA nadir < 0.2 ng/mL. However, these age‐related differences were not associated with biochemical recurrence.
- Open Access
- 19 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (16) , e70369
Correlation Between Lower Lobe Dose Parameters and Radiation Pneumonitis in Definitive Radiation Therapy for Non‐Small Cell Lung Cancer
Background: This study examined whether lobar‐specific dose‐volume histogram (DVH) parameters add predictive information for radiation pneumonitis (RP) beyond conventional whole‐lung parameters in patients with non‐small cell lung cancer (NSCLC) undergoing definitive radiotherapy. Methods: We retrospectively analyzed 145 NSCLC patients treated between 2018 and 2023. Conventional whole‐lung parameters, including V5%, V20%, and mean lung dose (MLD), lobar‐specific parameters, including Low V20% (percentage of the bilateral lower lobes receiving ≥ 20 Gy), and clinical parameters were analyzed. The predictive performance of each parameter for Grade ≥ 2 RP was evaluated using receiver operating characteristic curve analysis. Associations with Grade ≥ 2 RP were assessed by Gray test and Fine‐Gray competing risks regression. Results: Grade ≥ 2 RP had an incidence of 41% (60/145) and showed significant associations with V20% ( p = 0.005), MLD ( p = 0.025), Low V5% ( p = 0.006), and Low V20% ( p = 0.003). In multivariate analysis, a high Brinkman Index (BI) (HR = 2.10, 95% CI: 1.27–3.48, p = 0.004) and high Low V20% (HR = 2.31, 95% CI: 1.12–4.74, p = 0.023) were independent predictors for Grade ≥ 2 RP. The correlation between V20% and Low V20% was moderate ( r = 0.505), with minimal multicollinearity (variance inflation factor 1.34). Conclusion: Low V20% was independently associated with Grade ≥ 2 RP and may provide complementary information to conventional whole‐lung DVH parameters and BI. This simple lobar‐specific parameter may help refine pretreatment RP risk stratification, although external validation is required before its incorporation into individualized planning constraints.
- 19 August 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (16) , e70369
Open AccessCorrelation Between Lower Lobe Dose Parameters and Radiation Pneumonitis in Definitive Radiation Therapy for Non‐Small Cell Lung Cancer
Background: This study examined whether lobar‐specific dose‐volume histogram (DVH) parameters add predictive information for radiation pneumonitis (RP) beyond conventional whole‐lung parameters in patients with non‐small cell lung cancer (NSCLC) undergoing definitive radiotherapy. Methods: We retrospectively analyzed 145 NSCLC patients treated between 2018 and 2023. Conventional whole‐lung parameters, including V5%, V20%, and mean lung dose (MLD), lobar‐specific parameters, including Low V20% (percentage of the bilateral lower lobes receiving ≥ 20 Gy), and clinical parameters were analyzed. The predictive performance of each parameter for Grade ≥ 2 RP was evaluated using receiver operating characteristic curve analysis. Associations with Grade ≥ 2 RP were assessed by Gray test and Fine‐Gray competing risks regression. Results: Grade ≥ 2 RP had an incidence of 41% (60/145) and showed significant associations with V20% ( p = 0.005), MLD ( p = 0.025), Low V5% ( p = 0.006), and Low V20% ( p = 0.003). In multivariate analysis, a high Brinkman Index (BI) (HR = 2.10, 95% CI: 1.27–3.48, p = 0.004) and high Low V20% (HR = 2.31, 95% CI: 1.12–4.74, p = 0.023) were independent predictors for Grade ≥ 2 RP. The correlation between V20% and Low V20% was moderate ( r = 0.505), with minimal multicollinearity (variance inflation factor 1.34). Conclusion: Low V20% was independently associated with Grade ≥ 2 RP and may provide complementary information to conventional whole‐lung DVH parameters and BI. This simple lobar‐specific parameter may help refine pretreatment RP risk stratification, although external validation is required before its incorporation into individualized planning constraints.
- Open Access
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (2) , 66-73
Prognostic Value of EGFR Mutation Subtypes After Linac-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis From EGFR-Mutated Non-Small Cell Lung Cancer
Matsuda R, et al. Brain Tumor Res Treat. 2026 Apr;14(2):66-73. https://doi.org/10.14791/btrt.2025.0042
- 1 January 2026
- Published by XMLink in Brain Tumor Research and Treatment
- Vol. 14 (2) , 66-73
Open AccessPrognostic Value of EGFR Mutation Subtypes After Linac-Based Stereotactic Radiosurgery or Fractionated Stereotactic Radiotherapy for Brain Metastasis From EGFR-Mutated Non-Small Cell Lung Cancer
Matsuda R, et al. Brain Tumor Res Treat. 2026 Apr;14(2):66-73. https://doi.org/10.14791/btrt.2025.0042
Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer
Background: Androgen deprivation therapy (ADT) is used in the management of prostate cancer. Post‐therapy recovery from the induced hypogonadal state is protracted and correlates with diminished quality of life (QOL). Objective: This study assessed the impact of short‐term ADT on sexual health following brachytherapy. Materials and methods: The study included patients administered brachytherapy with or without short‐term neoadjuvant ADT (≤6 months) at our institution from 2010 to 2018. Serum total testosterone levels, chronological changes in erectile function, and health‐related QOL were evaluated. Results: Of 139 participants, 41 received neoadjuvant ADT (median, 4 months). Sexual health inventory for men (SHIM) scores and sexual function domain of the expanded prostate cancer index composite (EPIC) scores deteriorated significantly up to 36 months post‐treatment in patients receiving brachytherapy with neoadjuvant ADT compared to those without. A significant decline was observed in the sexual bother domain of the EPIC scores of patients without neoadjuvant ADT up to 6 months post‐treatment relative to those with neoadjuvant ADT. Total testosterone levels in the brachytherapy with neoadjuvant ADT group gradually recovered post‐treatment and were similar to those in the brachytherapy without neoadjuvant ADT group after 12‐month treatment. Neoadjuvant ADT and a lower pre‐treatment SHIM score were risk factors for severe erectile dysfunction 12 months after treatment. Discussion: Restoring sexual health extends beyond the normalization of testosterone levels following cessation of ADT. ADT significantly influences erectile dysfunction after brachytherapy. Our research identified a time lag between the restoration of testosterone levels and the improvement of erectile function and sexual QOL. We hypothesized that individuals undergoing ADT had diminished sexual distress, attributable to fewer opportunities for sexual engagement than their untreated counterparts. Conclusion: Persistent sexual dysfunction occurs despite the normalization of testosterone levels post‐ADT. Understanding sexual QOL changes following brachytherapy with ADT will help guide treatment recommendations and patient decision‐making.
Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer
Background: Androgen deprivation therapy (ADT) is used in the management of prostate cancer. Post‐therapy recovery from the induced hypogonadal state is protracted and correlates with diminished quality of life (QOL). Objective: This study assessed the impact of short‐term ADT on sexual health following brachytherapy. Materials and methods: The study included patients administered brachytherapy with or without short‐term neoadjuvant ADT (≤6 months) at our institution from 2010 to 2018. Serum total testosterone levels, chronological changes in erectile function, and health‐related QOL were evaluated. Results: Of 139 participants, 41 received neoadjuvant ADT (median, 4 months). Sexual health inventory for men (SHIM) scores and sexual function domain of the expanded prostate cancer index composite (EPIC) scores deteriorated significantly up to 36 months post‐treatment in patients receiving brachytherapy with neoadjuvant ADT compared to those without. A significant decline was observed in the sexual bother domain of the EPIC scores of patients without neoadjuvant ADT up to 6 months post‐treatment relative to those with neoadjuvant ADT. Total testosterone levels in the brachytherapy with neoadjuvant ADT group gradually recovered post‐treatment and were similar to those in the brachytherapy without neoadjuvant ADT group after 12‐month treatment. Neoadjuvant ADT and a lower pre‐treatment SHIM score were risk factors for severe erectile dysfunction 12 months after treatment. Discussion: Restoring sexual health extends beyond the normalization of testosterone levels following cessation of ADT. ADT significantly influences erectile dysfunction after brachytherapy. Our research identified a time lag between the restoration of testosterone levels and the improvement of erectile function and sexual QOL. We hypothesized that individuals undergoing ADT had diminished sexual distress, attributable to fewer opportunities for sexual engagement than their untreated counterparts. Conclusion: Persistent sexual dysfunction occurs despite the normalization of testosterone levels post‐ADT. Understanding sexual QOL changes following brachytherapy with ADT will help guide treatment recommendations and patient decision‐making.
- 28 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (12) , 1343-1350
Duration of α-1 adrenergic antagonist administration after low-dose-rate brachytherapy for prostate cancer
Background: Urinary dysfunction is an adverse event of low-dose-rate brachytherapy (LDR-BT) in patients with prostate cancer. We aimed to examine the time to α-1 adrenergic antagonist withdrawal after LDR-BT initiation. Methods: We retrospectively evaluated 1663 patients who underwent LDR-BT at our hospital during 2004–2022. Results: Overall, 1485/1663 (89.3%) patients were able to stop using α-1 adrenergic antagonists, 1111 (66.8%) of them within 1 year of LDR-BT. Risk factors for prolonged time to withdrawal were age ≥70 years, taking agents for lower urinary tract symptoms prior to LDR-BT, an International Prostate Symptom Score ≥8, an Overactive Bladder Symptom Score ≥3 and a residual urine volume ≥20 ml. Of the patients who were able to stop taking α-1 adrenergic antagonists, 357/1485 (24.0%) required resumption, 218 (61.1%) of whom did so between 1 and 3 years after LDR-BT. This period matched the period of transient worsening of the urinary symptom score. Finally, multivariable analysis identified supplemental external beam radiotherapy and an Overactive Bladder Symptom Score ≥3 as independent risk factors for α-1 adrenergic antagonist resumption. Conclusions: Withdrawal of α-1 adrenergic antagonists was possible in 66.8% of patients within 1 year of LDR-BT. Our results suggest that patients who are older or have pre-treatment LUTS may have prolonged deterioration of urinary dysfunction after treatment. Resumption of α-1 adrenergic antagonists 1–3 years after treatment may be associated with urinary symptom flares, and close attention is necessary for patients with supplemental external beam radiotherapy and a high pretreatment Overactive Bladder Symptom Score.
- 28 August 2024
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 54 (12) , 1343-1350
Duration of α-1 adrenergic antagonist administration after low-dose-rate brachytherapy for prostate cancer
Background: Urinary dysfunction is an adverse event of low-dose-rate brachytherapy (LDR-BT) in patients with prostate cancer. We aimed to examine the time to α-1 adrenergic antagonist withdrawal after LDR-BT initiation. Methods: We retrospectively evaluated 1663 patients who underwent LDR-BT at our hospital during 2004–2022. Results: Overall, 1485/1663 (89.3%) patients were able to stop using α-1 adrenergic antagonists, 1111 (66.8%) of them within 1 year of LDR-BT. Risk factors for prolonged time to withdrawal were age ≥70 years, taking agents for lower urinary tract symptoms prior to LDR-BT, an International Prostate Symptom Score ≥8, an Overactive Bladder Symptom Score ≥3 and a residual urine volume ≥20 ml. Of the patients who were able to stop taking α-1 adrenergic antagonists, 357/1485 (24.0%) required resumption, 218 (61.1%) of whom did so between 1 and 3 years after LDR-BT. This period matched the period of transient worsening of the urinary symptom score. Finally, multivariable analysis identified supplemental external beam radiotherapy and an Overactive Bladder Symptom Score ≥3 as independent risk factors for α-1 adrenergic antagonist resumption. Conclusions: Withdrawal of α-1 adrenergic antagonists was possible in 66.8% of patients within 1 year of LDR-BT. Our results suggest that patients who are older or have pre-treatment LUTS may have prolonged deterioration of urinary dysfunction after treatment. Resumption of α-1 adrenergic antagonists 1–3 years after treatment may be associated with urinary symptom flares, and close attention is necessary for patients with supplemental external beam radiotherapy and a high pretreatment Overactive Bladder Symptom Score.
- 5 April 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 195, 110269
Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes
- 5 April 2024
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 195, 110269
Reirradiation for recurrent gynecologic cancer using high-dose-rate brachytherapy in Japan: A multicenter survey on practice patterns and outcomes
- Open Access
- 15 August 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (2) , 101353
Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy
- 15 August 2023
- Published by Elsevier in Advances in Radiation Oncology
- Vol. 9 (2) , 101353
Open AccessCirculating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy
- 17 March 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 183, 109630
Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402)
- 17 March 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 183, 109630
Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402)
- Open Access
Gastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy
We aimed to evaluate the response to definitive radiotherapy (RT) for cervical cancer based on histological subtypes and investigate prognostic factors in adenocarcinoma (AC). Of the 396 patients treated with definitive RT between January, 2010 and July, 2020, 327 patients met the inclusion criteria, including 275 with squamous cell carcinoma (SCC) and 52 with AC restaged based on the 2018 International Federation of Gynecology and Obstetrics staging system. Patient characteristics, response to RT, and prognoses of SCC and AC were evaluated. The complete response (CR) rates were 92.4% and 53.8% for SCC and AC, respectively (p < 0.05). Three-year overall survival and progression-free survival (PFS) rates of SCC were significantly higher than those of AC (88.6% vs. 74.1%, p < 0.05 and 76.3% vs. 59.3%, p < 0.05, respectively). Among the AC population, univariate and multivariate analyses were performed to examine prognostic factors associated with non-complete response (CR). In the multivariate analysis, gastric-type adenocarcinoma (GAS) was associated with non-CR in AC (adjusted odds ratio, 12.2; 95% confidence interval 1.0–145.6; p < 0.05). The 3-year PFS rate in patients with GAS was significantly lower than that in patients with other histological types of AC (44.4% vs. 66.7%, p < 0.05). Definitive RT for cervical cancer was significantly less effective for AC than for SCC. GAS was the only independent prognostic factor associated with non-CR in AC.
Open AccessGastric-Type Adenocarcinoma of the Uterine Cervix Associated with Poor Response to Definitive Radiotherapy
We aimed to evaluate the response to definitive radiotherapy (RT) for cervical cancer based on histological subtypes and investigate prognostic factors in adenocarcinoma (AC). Of the 396 patients treated with definitive RT between January, 2010 and July, 2020, 327 patients met the inclusion criteria, including 275 with squamous cell carcinoma (SCC) and 52 with AC restaged based on the 2018 International Federation of Gynecology and Obstetrics staging system. Patient characteristics, response to RT, and prognoses of SCC and AC were evaluated. The complete response (CR) rates were 92.4% and 53.8% for SCC and AC, respectively (p < 0.05). Three-year overall survival and progression-free survival (PFS) rates of SCC were significantly higher than those of AC (88.6% vs. 74.1%, p < 0.05 and 76.3% vs. 59.3%, p < 0.05, respectively). Among the AC population, univariate and multivariate analyses were performed to examine prognostic factors associated with non-complete response (CR). In the multivariate analysis, gastric-type adenocarcinoma (GAS) was associated with non-CR in AC (adjusted odds ratio, 12.2; 95% confidence interval 1.0–145.6; p < 0.05). The 3-year PFS rate in patients with GAS was significantly lower than that in patients with other histological types of AC (44.4% vs. 66.7%, p < 0.05). Definitive RT for cervical cancer was significantly less effective for AC than for SCC. GAS was the only independent prognostic factor associated with non-CR in AC.
- Open Access
High Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model
Pancreatic cancer is an extremely treatment-resistant neoplasm to chemotherapy and immunotherapy. The combination of photon beam irradiation and anti-CTLA-4 antibody (C4) for the anti-tumor effect enhancement at local and distant tumors (abscopal tumors) was investigated using the pancreatic ductal adenocarcinoma (PDAC) mouse model. Pan02 cells were bilaterally inoculated to both legs of C57BL/6 mice. High dose photon beams in a hypofractionation or a single fraction were delivered to the tumors on one leg. Monotherapy with C4 via i.p. was not effective for PDAC. The high dose irradiation to the local tumors produced significant shrinkage of irradiated tumors but did not induce the abscopal responses. In contrast, the combination therapy of high dose photon beam irradiation in both hypofractionation and a single fraction with C4 enhanced the anti-tumor effect for abscopal tumors with significantly prolonged overall survival. The flow cytometric analysis revealed that the combination therapy dramatically decreased the regulatory T cell (Treg) proportion while increasing the cytotoxic T lymphocytes in both local and abscopal tumors. These results suggest that high dose photon beam irradiation plays an important role in C4 therapy to enhance the abscopal response with immune microenvironment changes in PDAC, regardless of the fractionation in radiation therapy.
Open AccessHigh Dose Local Photon Irradiation Is Crucial in Anti-CTLA-4 Antibody Therapy to Enhance the Abscopal Response in a Murine Pancreatic Carcinoma Model
Pancreatic cancer is an extremely treatment-resistant neoplasm to chemotherapy and immunotherapy. The combination of photon beam irradiation and anti-CTLA-4 antibody (C4) for the anti-tumor effect enhancement at local and distant tumors (abscopal tumors) was investigated using the pancreatic ductal adenocarcinoma (PDAC) mouse model. Pan02 cells were bilaterally inoculated to both legs of C57BL/6 mice. High dose photon beams in a hypofractionation or a single fraction were delivered to the tumors on one leg. Monotherapy with C4 via i.p. was not effective for PDAC. The high dose irradiation to the local tumors produced significant shrinkage of irradiated tumors but did not induce the abscopal responses. In contrast, the combination therapy of high dose photon beam irradiation in both hypofractionation and a single fraction with C4 enhanced the anti-tumor effect for abscopal tumors with significantly prolonged overall survival. The flow cytometric analysis revealed that the combination therapy dramatically decreased the regulatory T cell (Treg) proportion while increasing the cytotoxic T lymphocytes in both local and abscopal tumors. These results suggest that high dose photon beam irradiation plays an important role in C4 therapy to enhance the abscopal response with immune microenvironment changes in PDAC, regardless of the fractionation in radiation therapy.